* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Figures Slideset () - Annals of Internal Medicine
Survey
Document related concepts
Transcript
From: Outcomes With Concurrent Use of Clopidogrel and Proton-Pump InhibitorsA Cohort Study Ann Intern Med. 2010;152(6):337-345. doi:10.7326/0003-4819-152-6-201003160-00003 Figure Legend: Study flow diagram.* Prescription days of supply recently ended, so the person was neither a current user nor a nonuser. Date of download: 5/13/2017 Copyright © American College of Physicians. All rights reserved. From: Outcomes With Concurrent Use of Clopidogrel and Proton-Pump InhibitorsA Cohort Study Ann Intern Med. 2010;152(6):337-345. doi:10.7326/0003-4819-152-6-201003160-00003 Figure Legend: Distribution of person-years of follow-up, according to baseline propensity score (probability of baseline PPI use), for PPI users and nonusers.Vertical lines indicate deciles for the propensity score. PPI = proton-pump inhibitor. Date of download: 5/13/2017 Copyright © American College of Physicians. All rights reserved. From: Outcomes With Concurrent Use of Clopidogrel and Proton-Pump InhibitorsA Cohort Study Ann Intern Med. 2010;152(6):337-345. doi:10.7326/0003-4819-152-6-201003160-00003 Figure Legend: HRs for gastroduodenal and other bleeding, according to PPI use.GI = gastrointestinal; HR = hazard ratio; PPI = proton-pump inhibitor. * Rate is per 1000 person-years. Analysis by PPI dose and individual drug excludes person-time with concurrent use of multiple PPIs. Date of download: 5/13/2017 Copyright © American College of Physicians. All rights reserved. From: Outcomes With Concurrent Use of Clopidogrel and Proton-Pump InhibitorsA Cohort Study Ann Intern Med. 2010;152(6):337-345. doi:10.7326/0003-4819-152-6-201003160-00003 Figure Legend: Risk for hospitalizations for gastroduodenal bleeding in current users of clopidogrel, according to concurrent use of PPIs.“Rate Difference” is for nonusers of PPIs versus current users and is adjusted for potential confounders. The individual risk factors are age 65 years or older, history of hospitalization for upper gastrointestinal disease or bleeding, recent use of anticoagulants, current use of other medications that increase bleeding risk (systemic corticosteroids, nonsteroidal anti-inflammatory drugs, or cyclooxygenase-2 inhibitors), and any hospital discharge in the past year. PPI = proton-pump inhibitor. Date of download: 5/13/2017 Copyright © American College of Physicians. All rights reserved. From: Outcomes With Concurrent Use of Clopidogrel and Proton-Pump InhibitorsA Cohort Study Ann Intern Med. 2010;152(6):337-345. doi:10.7326/0003-4819-152-6-201003160-00003 Figure Legend: HRs for serious CVD, according to PPI use.AMI = acute myocardial infarction; CV = cardiovascular; CVD = cardiovascular disease; HR = hazard ratio; PPI = proton-pump inhibitor; SCD = sudden cardiac death. * Rate is per 1000 person-years. Analysis by PPI dose and individual drug excludes person-time with concurrent use of multiple PPIs. Date of download: 5/13/2017 Copyright © American College of Physicians. All rights reserved. From: Outcomes With Concurrent Use of Clopidogrel and Proton-Pump InhibitorsA Cohort Study Ann Intern Med. 2010;152(6):337-345. doi:10.7326/0003-4819-152-6-201003160-00003 Figure Legend: End point of risk for serious cardiovascular disease in current clopidogrel users who had percutaneous coronary intervention with stenting during the qualifying hospitalization, according to concurrent PPI use.Unadjusted cumulative proportions with serious cardiovascular disease (nonfatal or fatal myocardial infarction, stroke, or other cardiovascular death) are shown. The dashed lines indicate the 95% CI for the PPI nonuser group. Both clopidogrel and PPI use status could change on each day of follow-up; thus, the cumulative proportions were calculated by using the method of Simon and Makuch (43). PPI = proton-pump inhibitor. Date of download: 5/13/2017 Copyright © American College of Physicians. All rights reserved.